A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 4, 2010, Pages 991-996

  Gorman, Greg S ^a   Coward, Lori U ^a   Freeman, Lea ^a   Noker, Pat E ^a   Beattie, Craig W ^b   Jia, Lee ^c  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b CDG Therapeutics   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Azurin p28; Cupredoxin bacterial redox protein; Liquid chromatography tandem mass spectrometry; Pharmacokinetics

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; FORMIC ACID; PEPTIDE FRAGMENT; PERCHLORIC ACID; PROTEIN P28;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STABILITY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; ANIMALS; AZURIN; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; MALE; MICE; MOLECULAR SEQUENCE DATA; TANDEM MASS SPECTROMETRY;

EID: 77955584665     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.06.006     Document Type: Article

References (18)

1. Taranta M., Bizzarri A.R., Cannistraro S. Probing the interaction between p53 and the bacterial protein azurin by single molecule force spectroscopy. J. Mol. Recognit. 2008, 21:63-70.
2. Punj V., Das Gupta T.K., Chakrabarty A.M. Bacterial cupredoxin azurin and its interactions with the tumor suppressor protein p53. Biochem. Biophys. Res. Commun. 2003, 312:109-114.
3. Yamada T., Fialho A.M., Punj V., Bratescu L., Gupta T.K., Chakrabarty A.M. Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity. Cell Microbiol. 2005, 7:1418-1431.
4. Apiyo D., Wittung-Stafshede P. Unique complex between bacterial azurin and tumor-suppressor protein p53. Biochem. Biophys. Res. Commun. 2005, 332:965-968.
5. Hong C.S., Yamada T., Hashimoto W., Fialho A.M., Das Gupta T.K., Chakrabarty A.M. Disrupting the entry barrier and attacking brain tumors: the role of the Neisseria H.8 epitope and the Laz protein. Cell Cycle 2006, 5:1633-1641.
6. Mahfouz M., Hashimoto W., Das Gupta T.K., Chakrabarty A.M. Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy. Plasmid 2007, 57:4-17.
7. Chaudhari A., Mahfouz M., Fialho A.M., Yamada T., Granja A.T., Zhu Y., Hashimoto W., Schlarb-Ridley B., Cho W., Das Gupta T.K., Chakrabarty A.M. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry 2007, 46:1799-1810.
8. Yamada T., Goto M., Punj V., Zaborina O., Chen M.L., Kimbara K., Majumdar D., Cunningham E., Das Gupta T.K., Chakrabarty A.M. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:14098-14103.
9. Punj V., Bhattacharyya S., Saint-Dic D., Vasu C., Cunningham E.A., Graves J., Yamada T., Constantinou A.I., Christov K., White B., Li G., Majumdar D., Chakrabarty A.M., Das Gupta T.K. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 2004, 23:2367-2378.
10. Jia L., Noker P.E., Piazza G.A., Leuschner C., Hansel W., Gorman G.S., Coward L.U., Tomaszewski J. Pharmacokinetics and pharmacodynamics of Phor21-βCG(ala), a lytic peptide conjugate. J. Pharm. Pharmacol. 2008, 60:1441-1448.
11. Coward L.C., Kerstner-Wood, Noker P., Gorman G.S., Pellecchia M., Reed J.C., Jia L. Quantitative determination of Apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS. J. Pharm. Biomed. Anal. 2006, 42:581-586.
12. Jia L., Yu L., Linnik D.M., Jack R.M. Stability and pharmacokinetics of LJP 920, an octameric Gal (beta1-3) Gal conjugate for the inhibition of xenotransplantation rejection. J. Pharm. Pharmacol. 2001, 53:999-1005.
13. Wong H., Jia L., Camden J., Weitman S. Liquid chromatography-mass spectrometry assay of a thiodiazole derivative in mice: application to pharmacokinetic studies. J. Chromatogr. 2001, 765:55-62.
14. Jia L., Tomaszewski J.E., Noker P.E., Gorman G.S., Glaze E., Protopopova M. Simultaneous determination of pharmacokinetic properties of three anti-tubercular ethambutol analogs resulting from combinatorial lead optimization. J. Pharm. Biomed. Anal. 2005, 37:23-33.
15. Song M., Wang L., Hang T., Wen A., Yang L., Jia L. Rapid and sensitive liquid chromatography-tandem mass spectrometry for rasagiline: assay development, validation and application to a human pharmacokinetic study. J. Chromatogr. 2008, 875:515-521.
16. Jia L., Coward L.C., Kerstner-Wood, Gorman G.S., Noker P., Kitada S., Pellecchia M.P., Reed J.C. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Cancer Chemother. Pharmacol. 2008, 61:63-73.
17. Jia L., Liu X.D. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr. Drug Metab. 2007, 8:822-829.
18. FDA, Guidance for Industry: Bioanalytical Method Validation, May, 2001 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.